摘要
目的 探讨三种方案治疗老年慢性阻塞性肺疾病并发社区获得性肺炎的成本-效果分析.方法 将2010年1月～2013年3月在浙江省温州市文成县人民医院呼吸内科住院的78例患者随机均分为三组,每组26例,分别给予头孢呋辛加阿奇霉素（A组）、左氧氟沙星（B组）、头孢哌酮-舒巴坦钠（C组）治疗,比较三组之间的药物有效率、细菌清除率及药物不良反应发生率,并利用药物经济学进行成本-效果分析.结果 三种药物有效率分别为76.9％、80.8％、80.8％,差异无统计学意义（P＞0.05）,细菌清除率分别为81.8％、82.6％、87.0％,差异无统计学意义（P＞0.05）,且药物不良反应少,差异无统计学意义（P＞0.05）；成本-效果比比较：有效率分别为17.3％、14.9％、21.2％,细菌清除率分别为16.3％、14.6％、19.7％,B组成本-效果比最小.结论 左氧氟沙星治疗老年慢性阻塞性肺疾病并发社区获得性肺炎效果显著,安全可靠,值得推广应用.
Objective To investigate the relationship between cost and clinical effectiveness of three kinds of thera- peutic schems in treatment of elderly patients with community acquired pneumonia with chronic obstructive pulmonary disease. Methods All of 78 elderly patients were randomly divided into three groups, which were respectively treated with Cefuroxime combined with Azithromycin （group A）, Levofloxacin （group B） and Cefoperazone - sulbactam（group C）. The efficiency, bacterial clearance rate and incidence of adverse drug reactions were compared between the three groups, also the pharmacoeconomic principles was used for cost-effectiveness analysis. Results For group A, B and C, effectiveness respectively were 76.9%, 80.8%, 80.8%, there was no statistically significant difference （P 〉 0.05）, bacterial clearance rates were 81.8%, 82.6%, 87.0%, there was no statistically significant difference （P 〉 0.05）, and the incidence of adverse drug reactions were low, there was no statistically significant difference （P 〉 0.05）; the cost-effectiveness ratio respectively were that, effectiveness： 17.3%, 14.9%, 21.2%, bacterial clearance rates： 16.3%, 14.6%, 19.7%, the cost-effectiveness ratio of group B was the smallest. Conclusion Levofloxacin treatment elderly patients with commu- nity acquired pneumonia with chronic obstructive pulmonary disease is effective, safe and reliable, and worthy of clini- cal application.
出处
《中国医药导报》
CAS
2013年第26期122-124,共3页
China Medical Herald
基金
浙江省文成县科技局资助项目(编号201265)
